Aditum Bio Management Company, LLC

Institutional venture firmSEC venture capital fund adviser· Oakland, Californiaaditumbio.com

Aditum Bio is a new model of biotech venture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines.

In the firm's own words, from its website.

Reported fund assets
$773M
sum of its funds' Form ADV filings, last 30 months
New companies, 12 mo
None
Investment team
5
Latest vintage
2022
As of · the latest observation of this organization; filed figures are as of its latest Form ADV

4 additional team members, 3 events, 1 verified contact (1 firm phone)

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. 1 company
    portfolio raising

    One portfolio company has new financing on record in 6 months without this firm named on the round; the latest on 25 Jun 2026 ($62M round).

    A portfolio company raising again is a follow-on decision for the firm and a co-investment opening for others.

    FactPress release wires (PR Newswire, GlobeNewswire)For Co-investors, LPs, lendersInvestments →

People to know

View all people

Relationship network

12 connected entities

From financing rounds and every investor named in them, Form ADV and Form D filings, the firm's funds and team, and disclosed LP commitments in the venture capital graph. A round's amount is the size of the round, not money that moved between two investors.

Some relationships on this record are counted rather than named here. They open with the full profile.

Click any name or line for the rounds and sources behind it. Line weight is rounds together; dashed lines are inferred.

Reading the network
  • Company
  • Fund or vehicle
  • Person
›How strength and recency are read

Co-investors are read from the rounds: three or more shared rounds is a strong observed relationship, two a repeat co-investor, one a single round. Funds and people are structural. Nothing is scored that a reader cannot check.

Darker lines were active in the last 24 months or are current; lighter lines are older or undated.

How am I connected?

Name your firm, a company or a person, and DFX finds the published routes to Aditum Bio Management Company, LLC: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.

See how you connect to Aditum Bio Management Company, LLC

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Investing

2 companies on record, 0 new in 12 months

Investments on record

2 companies, 0 partner-attributed
CompanyRoundRolePartnerRound sizeThis investorDateSource
Kalexo Bioportfolio listingunknownunknownunknownunknownOct 1, 2026Fact Firm website
Oblenio Bioportfolio listingunknownunknownunknownunknownOct 1, 2026Fact Firm website

Stated thesis versus observed behaviour

2 observed deals
Stated (the firm’s website)
Sectors
biotech
Stages
not stated or not yet read
Geography
united states
Check size
not stated; DFX does not estimate checks from round sizes
Self-described
venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 100%
lead rate no observed dealsfollow-on rate no observed dealsnew companies, 12 months 0

Team

7 current, 1 departed

Decision makers

who to call first, and why; then everyone else by function
  • Joseph Jimenez · Managing Director
    Why this person: Managing director; Named with investment responsibility
  • Joshua Reuben Gertsman · Managing Director Of Aditum
    Why this person: Managing director; Named with investment responsibility
Who else at this firm · 1 person, grouped by function
Finance, operations and compliance (1)
  • Julie Hasmukh Shah · Chief Compliance Officer
    Why this person: Chief Compliance Officer at the firm

Ranked by the role the firm or its filing states, a route on file and deals led. Every reason is read from the record, never inferred. Routes are published by the person or the firm (their bio, the team page or a filing) and are revealed on a plan; data bought from a provider is never shown, and a route printed at a firm the person has since left is held back.

Investment team

7 current, 1 departed
1 departed (kept with end dates)
  • Ilan David Zipkin · Managing Director Of Aditum Bio Gp 2, Llc · Jul 1, 2021 to Mar 28, 2024 Inference

Contacts

1 firm phone

1 firm phone on record, each with its source. Values open with the complete profile.

Funds and LPs

3 vehicles, 0 LPs disclosed

Funds and vehicles

3 reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
Aditum Bio Fund 2, L.P.Fund2022 adv first reportedActive deployment$180M
Mar 31, 2026
102$0
of $250M
Jul 14, 2021
Aditum Bio Fund 1, L.P.Fund2019 form d first saleMature$179M
Mar 31, 2026
228$133M
of $133M
Oct 23, 2020
Aditum Bio Fund 3, L.P.FundunknownUnknown$414M
Mar 31, 2026
134$0
of $400M
May 31, 2024

Limited partners

0 LPs, 0 disclosed commitments
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.

Known LPs and allocators

3 relationships across the firm's funds, from public pensions and the allocator graph
AllocatorTypeFundAmountDateSource
Vinik Family FoundationFOUNDATIONAditum Bio Fund 1, L.P.$1.9M
fair value on the foundation's return
reported as of Dec 31, 2024Fact IRS Form 990 / 990-PF e-file returns
Michael & Susan Dell FoundationFOUNDATIONAditum Bio Fund 3, L.P.$1.3M
fair value on the foundation's return
reported as of Dec 31, 2024Fact IRS Form 990 / 990-PF e-file returns
Vinik Family FoundationFOUNDATIONAditum Bio Fund 2, L.P.$444,232
fair value on the foundation's return
reported as of Dec 31, 2024Fact IRS Form 990 / 990-PF e-file returns

Relationships across DFX

0 co-investors · on 2 other DFX graphs

Co-investors

0 counted from shared deals, for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Across DFX and the capital chainon 2 other DFX graphs · 2 capital paths Show
Across DFX
  • The same institution is held on Allocators, RIA and Wealth, matched by identifier. See which records
Across the graphs

Aditum Bio Management Company, LLC is the same institution as 2 records in Allocators and RIA and Wealth.

Allocators1RIA and Wealth1

DFX found 2 relationships across 2 datasets

Which record it is in each graph, what it is called there, and how the two were matched.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Checking your plan…

Capital chain

Aditum Bio Management Company, LLC sits on 2 traced paths of capital across the graphs.

Allocator commitments to a manager

DFX traced 2 paths of capital through this record

Every record on each path, what it committed or lent, and as of when.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.

Checking your plan…

Evidence and history

8 dated events, 69 observations from 4 sources

Timeline

8 dated events
  1. Mar 31, 2026
    Aditum Bio Fund 3, L.P. first reported on Form ADV by Aditum Bio Management Company, LLC (Venture Capital Fund), GAV $413,710,839
    Fund first reported on Form ADVFundsInferenceAditum Bio Fund 3, L.P.Form ADV
  2. Mar 28, 2024
    Ilan David Zipkin (Managing Director Of Aditum Bio Gp 2, Llc) no longer on Schedule A of Aditum Bio Management Company, LLC
    Person leftPeopleInferenceIlan David ZipkinForm ADV
  3. Aug 1, 2022
    Chris Klee joined Schedule A of Aditum Bio Management Company, LLC as Managing Director Of Aditum Bio Gp 2, Llc
    Person joinedPeopleFactChris KleeForm ADV
  4. Mar 31, 2022
    Aditum Bio Fund 2, L.P. first reported on Form ADV by Aditum Bio Management Company, LLC (Venture Capital Fund), GAV $202,979,965
    Fund first reported on Form ADVFundsFactAditum Bio Fund 2, L.P.Form ADV
  5. Jul 1, 2021
    Praveena Kandula joined Schedule A of Aditum Bio Management Company, LLC as Managing Director Of Aditum Bio Gp 2, Llc
    Person joinedPeopleFactPraveena KandulaForm ADV

Identity and regulatory footprint

Address, phone, Form ADV filing and ownersForm ADV filed Mar 31, 2026 · 3 private fundsShow
Headquarters
Oakland, CAadviserinfo.sec.gov
Office address
unknownadviserinfo.sec.gov
Business phone
unknownadviserinfo.sec.gov
SEC adviser type
Exempt reporting adviseradviserinfo.sec.gov
SEC exemption claimed
Venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
Latest Form ADV
Mar 31, 2026
Private funds reported
3 (3 venture capital funds)adviserinfo.sec.gov
Private fund gross assets, adviser total
$773Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Owners on Schedule A
Trialspark, Inc. (Managing Director Of Aditum Bio Gp 1, Llc), owns under 5%

Classification history

Every classification this record has carried3 on recordShow
  1. Sep 23, 2026
    Institutional venture firm (confirmed, 95%)
    Venture manager, reported GAV $773M across 3 vehicles
  2. Sep 12, 2026
    Institutional venture firm (confirmed, 95%)
    Venture manager, reported GAV $358M across 3 vehicles
  3. Sep 12, 2026
    Institutional venture firm (confirmed, 95%)
    Venture manager, reported GAV $358M across 2 vehicles

Evidence

70 observations from 4 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
Why admittedVC exemption, VC funds reportedMar 31, 2026FactForm ADV
SEC exemption claimedVenture capital fund adviserMar 31, 2026FactForm ADV
SEC exemption claimedVenture capital fund adviserDec 21, 2024FactForm ADV
SEC adviser typeExempt reporting adviserMar 31, 2026FactForm ADV
SEC adviser typeExempt reporting adviserMar 31, 2026FactForm ADV
SEC adviser typeExempt reporting adviserDec 21, 2024FactForm ADV
First Form ADV filing2019-09-23Mar 31, 2026FactForm ADV
First Form ADV filing2019-09-23Dec 21, 2024FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-30Oct 1, 2026FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-29Sep 30, 2026FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-25Sep 26, 2026FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-23Sep 24, 2026FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-21Sep 23, 2026FactForm ADV
Adv history loadedadv-hist-1+panel:2026-09-22Sep 23, 2026FactForm ADV
Adv history loadedadv-hist-1Sep 12, 2026FactForm ADV
Latest Form ADV filing2026-03-31Mar 31, 2026FactForm ADV
Latest Form ADV filing2026-03-31Mar 31, 2026FactForm ADV
Latest Form ADV filing2024-12-21Dec 21, 2024FactForm ADV
SEC statusERA - ActiveMar 31, 2026FactForm ADV
SEC status effective2019-09-23Mar 31, 2026FactForm ADV
Venture share of reported funds1Mar 31, 2026FactForm ADV
Venture share of reported funds1Dec 21, 2024FactForm ADV
Business phoneMar 31, 2026FactForm ADV
Business phoneDec 21, 2024FactForm ADV
DescriptionOct 1, 2026Fact
DescriptionSep 16, 2026Fact
DescriptionSep 13, 2026Fact
HeadquartersOakland, CAMar 31, 2026FactForm ADV
HeadquartersOakland, CADec 21, 2024FactForm ADV
Office addressMar 31, 2026FactForm ADV
Office addressDec 21, 2024FactForm ADV
Self-described typeVenture capitalOct 1, 2026Fact
Self-described typeVenture capitalSep 16, 2026Fact
Self-described typeVenture capitalSep 13, 2026Fact
Legal formLimited Liability CompanyMar 31, 2026FactForm ADV
Legal formLimited Liability CompanyDec 21, 2024FactForm ADV
Portfolio pageOct 1, 2026Fact
Portfolio pageSep 16, 2026Fact
Portfolio pageSep 13, 2026Fact
Private funds reported3Mar 31, 2026FactForm ADV
Private funds reported3Mar 31, 2026FactForm ADV
Private funds reported2Dec 21, 2024FactForm ADV
Private fund gross assets (reported)$773MMar 31, 2026FactForm ADV
Private fund gross assets (reported)$773MMar 31, 2026FactForm ADV
Private fund gross assets (reported)$358MDec 21, 2024FactForm ADV
Schedule a diffsadiff-1Mar 31, 2026FactForm ADV
Stated geographyunited states
“geography words on the home page”
Oct 1, 2026Fact
Stated geographyunited states
“geography words on the home page”
Sep 16, 2026Fact
Stated geographyunited states
“geography words on the home page”
Sep 13, 2026Fact
Stated sectorsbiotech
“sector words on the home page”
Oct 1, 2026Fact
Stated sectorsbiotech
“sector words on the home page”
Sep 16, 2026Fact
Stated sectorsbiotech
“sector words on the home page”
Sep 13, 2026Fact
Team pageOct 1, 2026Fact
Team pageSep 16, 2026Fact
Team pageSep 13, 2026Fact
Venture funds reported3Mar 31, 2026FactForm ADV
Venture funds reported3Mar 31, 2026FactForm ADV
Venture funds reported2Dec 21, 2024FactForm ADV
WebsiteDec 21, 2024FactForm ADV
Site titleOct 1, 2026Fact
Site titleSep 16, 2026Fact
Site titleSep 13, 2026Fact
How this is scored
Scores, classification basis and filing advisersInstitutional venture firm, confirmedShow
Importance
31
moderate
Active deployment
0
low
Emerging
0
low
Freshness
100
high
Institutional venture firmSEC exempt reporting adviser

Venture manager, reported GAV $773M across 3 vehicles

The inputs behind each score
importance
gav: 0.57 · funds: 0.25 · people: 0.36 · investments: 0.11 · co investors: 0
active deployment
investments 12m: 0 · fund raising 18m: 0 · people joined 12m: 0 · vintage within 3y: 0 · latest investment at: not scored
emerging manager
fund count: 3 · reported gav: $773M · first adv filing: 2019-09-23 · years since first filing: 7

Fits, record history and connections

scored matches for this investor, every identity change, every edge

Record history

1 dated event on the change ledger, latest event first
  • Adviser's first ADV filing
    2019-09-23source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.